EXPERTS IN PEPTIDE DRUG DISCOVERY AND DEVELOPMENT
Discovery, Development & Partnerships
We are advancing next-generation peptide therapeutics through a focused, data-driven discovery engine, rooted in years of peptide drug discovery and strengthened by selected strategic partnerships.
Consult with Louise S. Dalbøge
Chief Science Officer
Choose the right, trustworthy discovery partner.
Collaboration with Gubra
Drug Discovery and Development
Combine deep peptide expertise with AI-driven discovery to rapidly deliver development candidates and advance successful programs.
R&D Pipeline
Explore our robust and growing pipeline of peptide pre-clinical and clinical programs.
streaMLine Platform
Synthesize and screen thousands of peptides, using machine-learning and advanced models to accelerate drug discovery.
Partnering
Partner with us to develop tomorrow’s novel peptide therapeutics.
balanced portfolio of internal & partnered programs
Gubra’s R&D Pipeline
Gubra’s R&D pipeline is driven by a strong focus on peptide drug discovery and development. We are advancing a growing portfolio of programs across key therapeutic areas, including metabolic, endocrine, and hematological disorders. Our deep expertise in peptides enables us to discover and develop innovative drug candidates, both through our proprietary initiatives and in close collaboration with strategic partners.
(urocortin-2 analog)
Background
With current weight loss treatments, 20–40% of body weight reduction comes from unwanted loss of lean mass (muscles, bones, internal organs). Gubra’s UCN2 program is developed for high quality weight loss. In preclinical models UCN2 prevented incretin induced lean mass loos while enhancing fat mass reduction.
Internal
Compound
Urocortin-2 analogue and a potent and highly selective Corticotropin-releasing hormone receptor 2 (CRHR2) agonist that has been designed for weekly dosing.
Background
Injectable peptide-based GLP-1 receptor (GLP1R) agonists have shown remarkable therapeutic success in the treatment of type2 diabetes and obesity, as a monotherapy or in combinations.
Internal
Compound
Undisclosed
Background
Despite significant advancements with approved anti-obesity medications, a substantial medical need persists. Current therapies, while effective for many, often fall short in delivering sustained, long-term and muscle preserving weight loss.
Internal
Compound
Undisclosed
Background
Undisclosed
Internal
Compound
Undisclosed
(amylin analog)
Background
AbbVie and Gubra announced a license agreement to develop an amylin analog for the treatment of obesity. The agreement enables the incorporation of GUB014295, an amylin analogue discovered and developed by Gubra, into AbbVie's global infrastructure (ABBV-295). Amylin is a naturally occurring hormone secreted by pancreatic beta cells that plays a crucial role in energy balance and glucose homeostasis. As a satiety signal, it activates pathways in the brain to suppress appetite and reduce food intake.
Partner
Compound
A long-acting amylin analog.
Clinical
The Phase 1 clinical trial is a two-part, single center, double-blind (within cohorts), randomized, placebo-controlled, single (Part 1) and multiple (Part 2) ascending subcutaneous dose study of GUB014295. Part 1 has been completed; Part 2 is ongoing. More information on this trial can be found at https://www.clinicaltrials.gov/ (NCT: 06144684).
(NPY2R agonist)
Background
BI 1820237, which is fully outlicensed to Boehringer Ingelheim, is a long-acting neuropeptide Y receptor type 2 (NPY2R) agonist. In October 2024, Boehringer Ingelheim discontinued its development for obesity. Potential opportunities outside the obesity indication are now being explored by Boehringer Ingelheim.
Partner
Compound
Undisclosed
(triple GLP-1/GIP/NPY2 agonist)
Background
BI 3034701 is an investigational, potential first in class triple GLP 1, GIP and NPY2 receptor agonist peptide being developed for the treatment of obesity and related metabolic diseases, based on Gubra discovered technology.
Partner
Compound
A long-acting triple agonist peptide with a potential to become a next-generation and first-in-class obesity treatment.
Clinical
BI 3034701 has completed a Phase 1, first in human, randomized, placebo controlled trial assessing safety, tolerability, and pharmacokinetics in healthy participants and individuals with overweight or obesity. Following completion of Phase 1, Boehringer Ingelheim plans to initiate Phase 2 clinical development in mid 2026 to further evaluate the compound’s potential. Under the collaboration and license agreement, Boehringer Ingelheim is responsible for global clinical development and commercialization.
Background
Further building on their history of successful partnership, Gubra and Boehringer Ingelheim have entered a collaboration taking a new approach to discover novel peptides to deliver innovative treatments with the aim of improving health outcomes for people living with obesity.
Partner
Compound
Undisclosed
(GLP-1R antagonist)
Background
AMX0318, a novel, long-acting GLP-1 receptor antagonist, was selected as a development candidate for post-bariatric hypoglycemia (PBH) and other rare diseases by Amylyx and was identified through a research collaboration with Gubra. AMX0318 has completed extensive preclinical evaluation, including stability, solubility, potency, in vivo pharmacokinetics and pharmacodynamics, and in vivo tolerability studies. Amylyx expects the program to advance into IND-enabling studies later this year with an IND targeted for 2027, pending successful completion of IND enabling studies.
Partner
Compound
A novel, long-acting GLP-1 receptor antagonist
Background
Undisclosed
Partner
Compound
Undisclosed
Background
Gubra and Camurus announced a collaboration and license agreement to develop a long-acting therapeutic option for treatment of hypoparathyroidism. This research and development program will combine Gubra’s parathyroid hormone (PTH) analogue, developed using its proprietary streaMLine peptide discovery platform, with Camurus’ FluidCrystal® technology to enable extended, patient-friendly dosing.
Partner
Compound
A long-acting PTH analogue.
MACHINE LEARNING-ASSISTED ANALYSIS OF THOUSANDS OF PEPTIDES
StreaMLine
At Gubra, we continuously advance our knowledge and innovate our technology. Visit our resource library to explore the latest publications on streaMLine, our in-house machine-learning platform.
We believe the most meaningful innovations happen together
That’s why we are eager to collaborate with forward-thinking partners to co-create transformative therapeutic options, blending our expertise to drive science and value forward.
Related pages
For further information
Contact us
Gubra
Hørsholm Kongevej 11B
2970 Hørsholm
Denmark
+45 3152 2650